Seizures occurred in 0.6% of patients given the drug, compared with none of those given the placebo. "Obviously, these cases were studied very, very carefully. In four of the five cases, there were other potential confounders," including brain metastases and receipt of intravenous lidocaine for a biopsy, Dr. Scher noted. "This is an extremely low frequency, and considering this patient population who are symptomatic post docetaxel, for us, it’s really a nonissue."
The symposium is sponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Urologic Oncology.
Medivation Inc. sponsored the trial. Dr. Scher disclosed that he is a consultant to and receives research funding from Medivation. Dr. Vogelzang disclosed relationships with numerous companies. Dr. Kibel reported that he is a consultant to Dendreon and Sanofi-Aventis.